Print

Purpose

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Advanced Renal Cell Carcinoma - Must have at least 1 lesion with measurable disease - Life expectancy of at least 3 months - Karnofsky Performance Status (KPS) must be =>70%

Exclusion Criteria

  • Patients/subjects with suspected or known central nervous system metastases unless adequately treated - Patients/subjects with autoimmune disease - Patients/subjects who need daily oxygen therapy Other protocol defined inclusion/exclusion criteria apply

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Nivolumab + Ipilimumab 		Nivolumab + Ipilimumab
  • Biological: Nivolumab
    Specified Dose on Specified Days
    Other names:
    • Opdivo
    • BMS-936558
  • Biological: Ipilimumab
    Specified Dose on Specified Days
    Other names:
    • BMS-734016
    • Yervoy
Experimental
Nivolumab + Relatlimab 		Nivolumab + Relatlimab
  • Biological: Nivolumab
    Specified Dose on Specified Days
    Other names:
    • Opdivo
    • BMS-936558
  • Biological: Relatlimab
    Specified Dose on Specified Days
    Other names:
    • BMS-986016
Experimental
Nivolumab + BMS-986205 		Nivolumab + BMS-986205
  • Biological: Nivolumab
    Specified Dose on Specified Days
    Other names:
    • Opdivo
    • BMS-936558
  • Drug: BMS-986205
    Specified Dose on Specified Days
Experimental
Nivolumab + BMS-813160 		Nivolumab + BMS-813160 (CCR2/5 dual antagonist)
  • Biological: Nivolumab
    Specified Dose on Specified Days
    Other names:
    • Opdivo
    • BMS-936558
  • Drug: BMS-813160
    Specified Dose on Specified Days

More Details

Status
Completed
Sponsor
Bristol-Myers Squibb

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.